<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               ADVERSE REACTIONS<BR>               <BR>                  The following adverse events were observed and have been reported in patients using propranolol.<BR>                  <BR>                     Cardiovascular: Bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.<BR>                  <BR>                     Central Nervous System: Lightheadedness, mental depression manifested by insomnia, lassitude, weakness, fatigue; catatonia; visual disturbances; hallucinations; vivid dreams; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. For immediate-release formulations, fatigue, lethargy, and vivid dreams appear dose-related.<BR>                  <BR>                     Gastrointestinal: Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, ischemic colitis.<BR>                  <BR>                     Allergic: Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, pharyngitis and agranulocytosis; erythematous rash, fever combined with aching and sore throat; laryngospasm, and respiratory distress.<BR>                  <BR>                     Respiratory: Bronchospasm.<BR>                  <BR>                     Hematologic: Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura.<BR>                  <BR>                     Autoimmune: Systemic lupus erythematosus (SLE).<BR>                  <BR>                     Skin and mucous membranes: Stevens-Johnson Syndrome, toxic epidermal necrolysis, dry eyes, exfoliative dermatitis, erythema multiforme, urticaria, alopecia, SLE-like reactions, and psoriasiform rashes. Oculomucocutaneous syndrome involving the skin, serous membranes and conjunctivae reported for a beta-blocker (practolol) have not been associated with propranolol.<BR>                  <BR>                     Genitourinary: Male impotence; Peyronieâ€™s disease.<BR>               <BR>               <BR>            <BR>         </P></DIV></HTML>